サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1631222

アルツハイマー病の診断と治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2032年）

Alzheimer's Disease Diagnostics & Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032

出版日
ページ情報
英文 237 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
アルツハイマー病の診断と治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2032年）
出版日: 2025年01月03日
発行: Fairfield Market Research
ページ情報: 英文 237 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のアルツハイマー病の診断と治療の市場規模は、技術の進歩、認知度の向上、世界のアルツハイマー病有病率の上昇に牽引され、堅調な成長を遂げると予測されます。CAGRは9.00％で、2025年には77億1,900万米ドル、2032年には141億5,000万米ドルに達すると予測されています。このような進歩は、この神経変性疾患の複雑性に対処するための精密な診断と革新的な治療法の必要性を強調しています。

衰弱性の神経変性疾患であるアルツハイマー病は、世界中のヘルスケアシステムに手ごわい課題を突きつけています。認知機能の低下や記憶障害を特徴とするこの疾患は、患者や介護者に大きな影響を与えます。神経画像診断やバイオマーカー同定などの診断法の進歩により、効果的な介入に不可欠な早期発見が容易になっています。しかし、治療は依然として複雑であり、疾患修飾療法や症状緩和策の研究が進められています。

世界の高齢化は市場成長の重要な促進要因です。平均寿命が延びるにつれてアルツハイマー病の有病率は上昇し、高度な診断と治療に対する緊急の需要が生じています。PET検査やMRI検査などの神経画像診断技術の革新と、診断における人工知能（AI）の統合により、早期発見とモニタリング能力が向上しています。メンタルヘルスを非人格化し、早期診断を促進する取り組みが診断率の向上につながり、市場成長をさらに後押ししています。

当レポートでは、世界のアルツハイマー病の診断と治療市場について調査し、市場の概要とともに、ソリューション別、販売チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナ・ロシア紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界のアルツハイマー病の診断と治療市場の見通し、2019年～2032年

  • 世界のアルツハイマー病の診断と治療市場の見通し、ソリューション別、金額（10億米ドル）、2019年～2032年
  • 世界のアルツハイマー病の診断と治療市場の見通し、販売チャネル別、金額（10億米ドル）、2019年～2032年
  • 世界のアルツハイマー病の診断と治療市場の見通し、地域別、金額（10億米ドル）、2019年～2032年

第4章 北米のアルツハイマー病の診断と治療市場の見通し、2019年～2032年

第5章 欧州のアルツハイマー病の診断と治療市場の見通し、2019年～2032年

第6章 アジア太平洋のアルツハイマー病の診断と治療市場の見通し、2019年～2032年

第7章 ラテンアメリカのアルツハイマー病の診断と治療市場の見通し、2019年～2032年

第8章 中東・アフリカのアルツハイマー病の診断と治療市場の見通し、2019年～2032年

第9章 競合情勢

  • 企業市場シェア分析、2024年
  • 競合ダッシュボード
  • 企業プロファイル
    • Roche Diagnostics
    • Sysmex Corporation
    • Fujirebio
    • PHC Holdings Corporation
    • Quest Diagnostics
    • Beckman Coulter, Inc.
    • Biogen
    • Novartis
    • Eisai Inc.
    • Pfizer Inc.

第10章 付録

目次

The global Alzheimer's disease diagnostics and treatment market is projected to witness robust growth, driven by technological advancements, increasing awareness, and the rising prevalence of Alzheimer's disease worldwide. With a compound annual growth rate (CAGR) of 9.00%, the market is expected to reach a valuation of USD 7.719 billion by 2025 and USD 14.15 billion by 2032. These advancements underline the need for precise diagnostics and innovative therapies to address the complexities of this neurodegenerative condition.

Market Insights

Alzheimer's disease, a debilitating neurodegenerative disorder, presents a formidable challenge to healthcare systems worldwide. The condition, marked by cognitive decline and memory impairment, significantly impacts patients and caregivers. Advances in diagnostics, including neuroimaging and biomarker identification, have facilitated early detection, which is critical for effective intervention. However, treatment remains complex, with ongoing research into disease-modifying therapies and symptomatic relief measures.

Key Market Drivers

  • 1. Aging Population: The world's aging population is a significant driver of market growth. As life expectancy rises, the prevalence of Alzheimer's increases, creating an urgent demand for advanced diagnostics and treatments.
  • 2. Technological Advancements: Innovations in neuroimaging techniques such as PET and MRI scans, along with the integration of artificial intelligence (AI) in diagnostics, have enhanced early detection and monitoring capabilities.
  • 3. Increased Awareness: Initiatives to destigmatize mental health and promote early diagnosis have led to higher diagnosis rates, further propelling market growth.

Business Opportunities

  • 1. Technological Integration: Emerging technologies such as AI and machine learning offer opportunities for enhanced diagnostics by analyzing complex datasets and identifying subtle biomarkers.
  • 2. Telemedicine and Digital Health: The adoption of telemedicine platforms provides accessible and personalized care for Alzheimer's patients, reducing the burden on traditional healthcare systems.
  • 3. Cognitive Rehabilitation: Virtual reality (VR) and augmented reality (AR) interventions present novel approaches for cognitive therapy, mitigating the effects of cognitive decline and offering interactive patient care.

Regional Analysis

  • 1. North America: Leading the market with a robust healthcare infrastructure, North America benefits from high disease prevalence, advanced diagnostic tools, and extensive research initiatives. Proactive integration of innovative solutions in clinical practice further cements its dominance.
  • 2. Asia Pacific: Emerging as the fastest-growing region, the Asia Pacific's large aging population, rising awareness, and expanding healthcare infrastructure contribute to its rapid growth. Countries such as China and India are witnessing heightened demand for advanced diagnostic tools and therapeutic options.
  • 3. Europe: Known for its well-established healthcare systems, Europe remains a key market for Alzheimer's diagnostics and treatment, supported by research activities and government initiatives.

Market Restraints

  • 1. Regulatory Challenges: Stringent approval processes for diagnostics and therapeutics extend development timelines and increase costs for market players.
  • 2. Reimbursement Limitations: Limited reimbursement policies restrict access to advanced diagnostic tools and treatments, imposing financial burdens on patients and healthcare systems.

Competitive Analysis

Prominent companies in the Alzheimer's diagnostics and treatment market include Biogen Inc., Eli Lilly and Company, and Pfizer Inc. These players are leveraging strategic collaborations, R&D initiatives, and technological advancements to maintain their market positions. Key strategies include:

  • Innovative Therapies: Companies are focusing on disease-modifying treatments, such as Biogen's Aducanumab, to address Alzheimer's at its core.
  • Strategic Alliances: Partnerships with healthcare providers and research institutions enable the rapid adoption of precision medicine in Alzheimer's care.
  • Expanded Diagnostic Portfolios: By investing in digital health solutions, companies like Pfizer aim to enhance early detection and monitoring capabilities.

Key Players

  • Biogen Inc.
  • AbbVie, Inc.
  • Teva Pharmaceuticals Ltd.
  • Eisai Co. Ltd.
  • Janssen Pharmaceuticals Inc.
  • Novartis AG
  • Zydus Lifesciences Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Ltd.

Market Segmentation:

By Product:

  • Therapeutics Cholinesterase Inhibitors NMDA Receptor Antagonists Manufactured Combination
  • Diagnostics Lumbar Diagnostics Test CT Scan MRI EEG PET scan

By Distribution Channel:

  • Institutional Sales Hospitals Specialty Clinics Diagnostic Centers
  • Retail Sales Retail Pharmacies Drug Stores Online Pharmacies

By Region:

  • North America
  • Europe
  • Asia Pacific
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Alzheimer's Disease Diagnostics & Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Alzheimer's Disease Diagnostics & Treatment Market Outlook, 2019 - 2032

  • 3.1. Global Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Solution, Value (US$ Bn), 2019 - 2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Therapeutics
        • 3.1.1.1.1. NMDA Receptor Antagonists
        • 3.1.1.1.2. Anti-Amyloid Monoclonal Antibodies
        • 3.1.1.1.3. Cholinesterase Inhibitors
        • 3.1.1.1.4. Manufactured Combinations
        • 3.1.1.1.5. Others
      • 3.1.1.2. Diagnostics
        • 3.1.1.2.1. Blood-based Biomarker Tests
        • 3.1.1.2.2. Brain Imaging Tests
        • 3.1.1.2.3. Computerized Cognitive Test and Devices
        • 3.1.1.2.4. CSF Biomarker Tests
        • 3.1.1.2.5. Others
  • 3.2. Global Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Institutional Sales
        • 3.2.1.1.1. Hospitals
        • 3.2.1.1.2. Specialty Clinics
        • 3.2.1.1.3. Diagnostic Centers
        • 3.2.1.1.4. Others
      • 3.2.1.2. Retail Sales
        • 3.2.1.2.1. Retail Pharmacies
        • 3.2.1.2.2. Online Pharmacies
  • 3.3. Global Alzheimer's Disease Diagnostics & Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Alzheimer's Disease Diagnostics & Treatment Market Outlook, 2019 - 2032

  • 4.1. North America Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Solution, Value (US$ Bn), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Therapeutics
        • 4.1.1.1.1. NMDA Receptor Antagonists
        • 4.1.1.1.2. Anti-Amyloid Monoclonal Antibodies
        • 4.1.1.1.3. Cholinesterase Inhibitors
        • 4.1.1.1.4. Manufactured Combinations
        • 4.1.1.1.5. Others
      • 4.1.1.2. Diagnostics
        • 4.1.1.2.1. Blood-based Biomarker Tests
        • 4.1.1.2.2. Brain Imaging Tests
        • 4.1.1.2.3. Computerized Cognitive Test and Devices
        • 4.1.1.2.4. CSF Biomarker Tests
        • 4.1.1.2.5. Others
  • 4.2. North America Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Institutional Sales
        • 4.2.1.1.1. Hospitals
        • 4.2.1.1.2. Specialty Clinics
        • 4.2.1.1.3. Diagnostic Centers
        • 4.2.1.1.4. Others
      • 4.2.1.2. Retail Sales
        • 4.2.1.2.1. Retail Pharmacies
        • 4.2.1.2.2. Online Pharmacies
  • 4.3. North America Alzheimer's Disease Diagnostics & Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 4.3.1.2. U.S. Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 4.3.1.3. Canada Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 4.3.1.4. Canada Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Alzheimer's Disease Diagnostics & Treatment Market Outlook, 2019 - 2032

  • 5.1. Europe Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Solution, Value (US$ Bn), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Therapeutics
        • 5.1.1.1.1. NMDA Receptor Antagonists
        • 5.1.1.1.2. Anti-Amyloid Monoclonal Antibodies
        • 5.1.1.1.3. Cholinesterase Inhibitors
        • 5.1.1.1.4. Manufactured Combinations
        • 5.1.1.1.5. Others
      • 5.1.1.2. Diagnostics
        • 5.1.1.2.1. Blood-based Biomarker Tests
        • 5.1.1.2.2. Brain Imaging Tests
        • 5.1.1.2.3. Computerized Cognitive Test and Devices
        • 5.1.1.2.4. CSF Biomarker Tests
        • 5.1.1.2.5. Others
  • 5.2. Europe Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Institutional Sales
        • 5.2.1.1.1. Hospitals
        • 5.2.1.1.2. Specialty Clinics
        • 5.2.1.1.3. Diagnostic Centers
        • 5.2.1.1.4. Others
      • 5.2.1.2. Retail Sales
        • 5.2.1.2.1. Retail Pharmacies
        • 5.2.1.2.2. Online Pharmacies
  • 5.3. Europe Alzheimer's Disease Diagnostics & Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 5.3.1.2. Germany Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.3. U.K. Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 5.3.1.4. U.K. Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.5. France Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 5.3.1.6. France Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.7. Italy Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 5.3.1.8. Italy Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.9. Turkey Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 5.3.1.10. Turkey Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.11. Russia Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 5.3.1.12. Russia Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.13. Rest of Europe Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 5.3.1.14. Rest of Europe Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Alzheimer's Disease Diagnostics & Treatment Market Outlook, 2019 - 2032

  • 6.1. Asia Pacific Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Solution, Value (US$ Bn), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Therapeutics
        • 6.1.1.1.1. NMDA Receptor Antagonists
        • 6.1.1.1.2. Anti-Amyloid Monoclonal Antibodies
        • 6.1.1.1.3. Cholinesterase Inhibitors
        • 6.1.1.1.4. Manufactured Combinations
        • 6.1.1.1.5. Others
      • 6.1.1.2. Diagnostics
        • 6.1.1.2.1. Blood-based Biomarker Tests
        • 6.1.1.2.2. Brain Imaging Tests
        • 6.1.1.2.3. Computerized Cognitive Test and Devices
        • 6.1.1.2.4. CSF Biomarker Tests
        • 6.1.1.2.5. Others
  • 6.2. Asia Pacific Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Institutional Sales
        • 6.2.1.1.1. Hospitals
        • 6.2.1.1.2. Specialty Clinics
        • 6.2.1.1.3. Diagnostic Centers
        • 6.2.1.1.4. Others
      • 6.2.1.2. Retail Sales
        • 6.2.1.2.1. Retail Pharmacies
        • 6.2.1.2.2. Online Pharmacies
  • 6.3. Asia Pacific Alzheimer's Disease Diagnostics & Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 6.3.1.2. China Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.3. Japan Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 6.3.1.4. Japan Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.5. South Korea Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 6.3.1.6. South Korea Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.7. India Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 6.3.1.8. India Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.9. Southeast Asia Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 6.3.1.10. Southeast Asia Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.11. Rest of Asia Pacific Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 6.3.1.12. Rest of Asia Pacific Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Alzheimer's Disease Diagnostics & Treatment Market Outlook, 2019 - 2032

  • 7.1. Latin America Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Solution, Value (US$ Bn), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Therapeutics
        • 7.1.1.1.1. NMDA Receptor Antagonists
        • 7.1.1.1.2. Anti-Amyloid Monoclonal Antibodies
        • 7.1.1.1.3. Cholinesterase Inhibitors
        • 7.1.1.1.4. Manufactured Combinations
        • 7.1.1.1.5. Others
      • 7.1.1.2. Diagnostics
        • 7.1.1.2.1. Blood-based Biomarker Tests
        • 7.1.1.2.2. Brain Imaging Tests
        • 7.1.1.2.3. Computerized Cognitive Test and Devices
        • 7.1.1.2.4. CSF Biomarker Tests
        • 7.1.1.2.5. Others
  • 7.2. Latin America Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Institutional Sales
        • 7.2.1.1.1. Hospitals
        • 7.2.1.1.2. Specialty Clinics
        • 7.2.1.1.3. Diagnostic Centers
        • 7.2.1.1.4. Others
      • 7.2.1.2. Retail Sales
        • 7.2.1.2.1. Retail Pharmacies
        • 7.2.1.2.2. Online Pharmacies
  • 7.3. Latin America Alzheimer's Disease Diagnostics & Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 7.3.1.2. Brazil Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.3. Mexico Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 7.3.1.4. Mexico Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.5. Argentina Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 7.3.1.6. Argentina Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.7. Rest of Latin America Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 7.3.1.8. Rest of Latin America Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Alzheimer's Disease Diagnostics & Treatment Market Outlook, 2019 - 2032

  • 8.1. Middle East & Africa Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Solution, Value (US$ Bn), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Therapeutics
        • 8.1.1.1.1. NMDA Receptor Antagonists
        • 8.1.1.1.2. Anti-Amyloid Monoclonal Antibodies
        • 8.1.1.1.3. Cholinesterase Inhibitors
        • 8.1.1.1.4. Manufactured Combinations
        • 8.1.1.1.5. Others
      • 8.1.1.2. Diagnostics
        • 8.1.1.2.1. Blood-based Biomarker Tests
        • 8.1.1.2.2. Brain Imaging Tests
        • 8.1.1.2.3. Computerized Cognitive Test and Devices
        • 8.1.1.2.4. CSF Biomarker Tests
        • 8.1.1.2.5. Others
  • 8.2. Middle East and Africa Alzheimer's Disease Diagnostics & Treatment Market Outlook, By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Institutional Sales
        • 8.2.1.1.1. Hospitals
        • 8.2.1.1.2. Specialty Clinics
        • 8.2.1.1.3. Diagnostic Centers
        • 8.2.1.1.4. Others
      • 8.2.1.2. Retail Sales
        • 8.2.1.2.1. Retail Pharmacies
        • 8.2.1.2.2. Online Pharmacies
  • 8.3. Middle East & Africa Alzheimer's Disease Diagnostics & Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 8.3.1.2. GCC Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.3. South Africa Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 8.3.1.4. South Africa Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.5. Egypt Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 8.3.1.6. Egypt Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.7. Nigeria Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 8.3.1.8. Nigeria Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.9. Rest of Middle East & Africa Alzheimer's Disease Diagnostics & Treatment Market By Solution, Value (US$ Bn), 2019 - 2032
      • 8.3.1.10. Rest of Middle East & Africa Alzheimer's Disease Diagnostics & Treatment Market By Sales Channel, Value (US$ Bn), 2019 - 2032
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2024
  • 9.2. Competitive Dashboard
  • 9.3. Company Profiles
    • 9.3.1. Roche Diagnostics
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
      • 9.3.1.3. Financial Overview
      • 9.3.1.4. Business Strategies and Development
    • 9.3.2. Sysmex Corporation
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
      • 9.3.2.3. Financial Overview
      • 9.3.2.4. Business Strategies and Development
    • 9.3.3. Fujirebio
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Financial Overview
      • 9.3.3.4. Business Strategies and Development
    • 9.3.4. PHC Holdings Corporation
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
      • 9.3.4.3. Financial Overview
      • 9.3.4.4. Business Strategies and Development
    • 9.3.5. Quest Diagnostics
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
      • 9.3.5.3. Financial Overview
      • 9.3.5.4. Business Strategies and Development
    • 9.3.6. Beckman Coulter, Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio
      • 9.3.6.3. Financial Overview
      • 9.3.6.4. Business Strategies and Development
    • 9.3.7. Biogen
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Product Portfolio
      • 9.3.7.3. Financial Overview
      • 9.3.7.4. Business Strategies and Development
    • 9.3.8. Novartis
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Product Portfolio
      • 9.3.8.3. Financial Overview
      • 9.3.8.4. Business Strategies and Development
    • 9.3.9. Eisai Inc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Product Portfolio
      • 9.3.9.3. Financial Overview
      • 9.3.9.4. Business Strategies and Development
    • 9.3.10. Pfizer Inc.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Product Portfolio
      • 9.3.10.3. Financial Overview
      • 9.3.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations